Antimicrobial susceptibility to sisomicin and netilmicin (Sch 20569) was determined on 164 clinical isolates using a broth microdilution method. Sisomicin was active against 86.1%, and netilmicin against 96.4%, of the isolates. In addition, netilmicin was active against 93.7% of the strains that were resistant to gentamicin, kanamycin, tobramycin, and sisomicin.
new drugs that could potentially replace gentamicin or be used whenever gentamicin cannot. This study compared the susceptibility of clinical isolates to two new aminoglycosides, sisomicin and netilmicin. Netilmicin is a semisynthetic derivative of sisomicin, which is produced by Micromonospora inyoensis. Netilmicin and sisomicin closely resemble gentamicin in molecular structure.
The organisms studied were initial clinical isolates identified by conventional methods in the clinical microbiology section of the Oklahoma City Veterans Administration Hospital. Disk diffusion susceptibility studies on 164 isolates showed: gentamicin (88.5% susceptible), kanamycin (58.8%), tobramycin (86.7%), and sisomicin (89.1%). Susceptibility testing results to gentamicin and sisomicin were identical in 161 (97.5%) of the isolates. Sixteen isolates were resistant to gentamicin, kanamycin, tobramycin, and sisomicin. Fifteen of these strains were resistant to sisomicin and susceptible to netilmicin as determined by MIC studies (Table 2) . One isolate, Proteus rettgeri F21, was resistant to both sisomicin and netilmicin. This isolate was susceptible to amikacin as determined by disk agar diffusion testing. Twelve of the sixteen strains were isolated from urinary tract sources.
The similarity of gentamicin and sisomicin has been previously mentioned (2, 5, 8, 9) . However, netilmicin has been reported to be significantly more active than gentamicin against clinical isolates of Enterobacteriaceae, Staphylococcus aureus, and Pseudomonas aeruginosa (6) . Another study (4) showed netilmicin to be effective against gentamicin-resistant Enterobacteriaceae. This report discloses netilmicin to be significantly more active than sisomicin. These differences in activity appear to be the result of distinct enzymes. Kabins et al. (4) found that gentamicin-resistant organisms possess an aminoglycoside-adenylating enzyme, whereas netilmicin resistance was associated with an acetylating enzyme. They also reported that Proteus sp. have an acetylating enzyme, which may explain (Table 2) higher MICs for two aminoglycoside-resistant Proteus rettgeri in this study. Since the MICs for Proteus mirabilis were lower than those for other Proteus sp. (Table 1) , the presence of acetylating enzymes may differ in the two groups.
This investigation shows P. aeruginosa to be susceptible to netilmicin, as determined by 
